Yvonne Buggy
Overview
Explore the profile of Yvonne Buggy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
181
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buggy Y, Cornelius V, Fogg C, Kasliwal R, Layton D, Shakir S
Drug Saf
. 2013 May;
36(7):521-31.
PMID: 23657823
Background: Varenicline (Champix(®)), launched in the UK in December 2006, is indicated for the treatment of smoking cessation in adults (≥18 years of age). In 2008, the Medicines and Healthcare...
2.
Willemen M, Mantel-Teeuwisse A, Buggy Y, Layton D, Straus S, Leufkens H, et al.
Drug Saf
. 2012 Oct;
35(12):1147-58.
PMID: 23061737
Background: Early treatment discontinuation will have a negative effect on a drug's benefit-risk profile if discontinuation occurs earlier in time than the positive effects of treatment. This non-persistence of therapy...
3.
Buggy Y, Cornelius V, Wilton L, Shakir S
Drug Saf
. 2011 May;
34(6):501-9.
PMID: 21585222
Background: Marketing authorization for rimonabant was withdrawn in October 2008, mainly because the psychiatric adverse effects could not be addressed by further risk minimization. Objective: The aim of the study...
4.
Buggy Y, Layton D, Fogg C, Shakir S
Epilepsia
. 2010 Feb;
51(5):818-29.
PMID: 20132298
Purpose: To monitor safety of oxcarbazepine, prescribed in primary care in England, using prescription-event monitoring (PEM). Methods: Postmarketing surveillance using observational cohort technique of PEM. Exposure data were obtained from...
5.
Iyer D, Buggy Y, OReilly K, Searle M
Nephrology (Carlton)
. 2009 Aug;
14(6):624.
PMID: 19712264
No abstract available.
6.
Mc Ilroy M, Fleming F, Buggy Y, Hill A, Young L
Endocr Relat Cancer
. 2006 Dec;
13(4):1135-45.
PMID: 17158759
Differential signalling between the two oestrogen receptor (ER) isoforms in the presence of tamoxifen has been described. We hypothesise that differential recruitment of the steroid receptor co-activator, SRC-3 to ER-alpha...
7.
Kelly L, Buggy Y, Hill A, ODonovan N, Duggan C, McDermott E, et al.
Tumour Biol
. 2005 Jul;
26(4):213-6.
PMID: 16006775
The BRMS1 (breast cancer metastasis suppressor 1) gene has been found to suppress metastasis in animal models without inhibiting primary tumor growth. The aim of this study was to measure...
8.
Myers E, Hill A, Kelly G, McDermott E, OHiggins N, Buggy Y, et al.
Clin Cancer Res
. 2005 Mar;
11(6):2111-22.
PMID: 15788656
Purpose: Associations between p160 coactivator proteins and the development of resistance to endocrine treatment have been described. We hypothesized that nuclear receptor coregulatory proteins may interact with nonsteroid receptors. We...
9.
OShea C, McKie N, Buggy Y, Duggan C, Hill A, McDermott E, et al.
Int J Cancer
. 2003 May;
105(6):754-61.
PMID: 12767059
The ADAMs (a disintegrin and metalloprotease) are membrane proteins containing both protease and adhesion domains and thus may be potentially important in cancer invasion and metastasis. The aim of our...